Paclitaxel and Cisplatin/ Carboplatin

Phase 2Small molecule

Paclitaxel and Cisplatin/ Carboplatin is one of 39 small molecule programs targeting Cervical Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cervical CancerActive, not recruiting

Cervical CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

380 competitors in Cervical Cancer

#DrugCompanyPhaseTrials

Paraplatin

AAvyxa

Phase 3

38 2

Keytruda

Merck & Co.

Phase 3

13 3

Camptosar

Pfizer

Phase 3

4 4

Alimta

EEagle Vision Pharmaceutical Corp.

Phase 3

4 5

Theraplaza

BBiotech Pharmaceutical Co., Ltd.

Phase 3

4 6

Navelbine

PPierre Fabre Medicament

Phase 3

3 7

Gemzar

GGynecologic Oncology Group

Phase 3

2 8

Velban

EEastern Cooperative Oncology Group

Phase 3

1 9

Rescue

Merck & Co.

Phase 3

1 10

HLX10

Shanghai Henlius Biotech

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 2Recruiting

Cervical Cancer

NCT06942416

Clinical

Trials by Indication[1]

Cervical Cancer1 trial

Iparomlimab and Tuvonralimab With Chemoradiation for the Treatment of Locally Recurrent and Oligometastatic Cervical Cancer

Recruiting·SShandong Cancer Hospital and Institute·Phase 2·NCT06942416·36 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Paclitaxel and Cisplatin/ Carboplatin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Paclitaxel and Cisplatin/ Carboplatin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Paclitaxel and Cisplatin/ Carboplatin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shandong Cancer Hospital and Institute company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SShandong Cancer Hospital and Institute

Paclitaxel and Cisplatin/ Carboplatin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Cervical Cancer1 trial

References

Drug Info

Quick Facts

Related News